

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
13 July 2023 (13.07.2023)



(10) International Publication Number  
**WO 2023/131329 A1**

(51) International Patent Classification:

C07K 16/46 (2006.01) C07K 16/28 (2006.01)  
C07K 16/44 (2006.01)

(21) International Application Number:

PCT/CN2023/071334

(22) International Filing Date:

09 January 2023 (09.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2022/070870

09 January 2022 (09.01.2022) CN

PCT/CN2022/117334

06 September 2022 (06.09.2022) CN

(71) Applicant: **I-MAB BIOPHARMA CO., LTD.** [CN/CN];  
Rm 802, 8F, 1Bld., West Tower, 88 Shangke Rd., Pudong,  
Shanghai 201210 (CN).

(72) Inventors: **JIANG, Wenqing**; Rm 802, 8F, 1Bld., West  
Tower, 88 Shangke Rd., Pudong, Shanghai 201210 (CN).  
**LI, Jian**; Rm 802, 8F, 1Bld., West Tower, 88 Shangke  
Rd., Pudong, Shanghai 201210 (CN). **CHEN, Xi**; Rm 802,  
8F, 1Bld., West Tower, 88 Shangke Rd., Pudong, Shanghai  
201210 (CN). **LIU, Yan**; Rm 802, 8F, 1Bld., West Tow-  
er, 88 Shangke Rd., Pudong, Shanghai 201210 (CN). **GUO,**  
**Bingshi**; Rm 802, 8F, 1Bld., West Tower, 88 Shangke Rd.,  
Pudong, Shanghai 201210 (CN).

(74) Agent: **GE CHENG & CO., LTD**; CHENG, David W.,  
Level 10, Tower E3, The Towers, Oriental Plaza, No. 1, East  
Chang An Avenue, Dongcheng District, Beijing 100738  
(CN).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,  
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,  
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,  
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,  
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,  
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,  
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MULTISPECIFIC CONSTRUCTS AND USES THEREOF

(57) Abstract: Provided are bispecific and multi-specific antibodies that target claudin 6 (CLDN6) and 4-1BB. These antibodies, in the absence of CLDN6-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN6-expressing cells, however, these antibodies can trigger CLDN6-dependent 4-1BB signaling, leading to potent immune response to the CLDN6-expressing tumor cells.

WO 2023/131329 A1